Novo Nordisk's Wegovy Higher Dose Gets UK Health Regulator Approval for Obesity Patients
MT Newswires Live
Jan 16
Novo Nordisk's (NVO) Wegovy in a maximum dose of up to 7.2 milligrams per week has received approval from the UK's Medicines and Healthcare products Regulatory Agency for patients with obesity only, the regulator said Friday.
The approval for the drug, chemically known as semaglutide, covers only patients with a body mass index of at least 30 that use the drug for weight management alongside diet and exercise, according to the agency.
Patients will be required to inject three doses of 2.4 mg, one after each other on the same day, the agency said.
Novo Nordisk shares were up 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.